RU2008130413A - Фармацевтическая композиция для лечения геморрагического шока и его последствий - Google Patents

Фармацевтическая композиция для лечения геморрагического шока и его последствий Download PDF

Info

Publication number
RU2008130413A
RU2008130413A RU2008130413/15A RU2008130413A RU2008130413A RU 2008130413 A RU2008130413 A RU 2008130413A RU 2008130413/15 A RU2008130413/15 A RU 2008130413/15A RU 2008130413 A RU2008130413 A RU 2008130413A RU 2008130413 A RU2008130413 A RU 2008130413A
Authority
RU
Russia
Prior art keywords
pro
arg
gly
peptide
glu
Prior art date
Application number
RU2008130413/15A
Other languages
English (en)
Russian (ru)
Inventor
Петер ПЕТЦЕЛЬБАУЭР (AT)
Петер ПЕТЦЕЛЬБАУЭР
Райнер ХЕННИНГ (CH)
Райнер ХЕННИНГ
Original Assignee
Фибрекс Медикал Рисерч Энд Девелопмент Гмбх (At)
Фибрекс Медикал Рисерч Энд Девелопмент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фибрекс Медикал Рисерч Энд Девелопмент Гмбх (At), Фибрекс Медикал Рисерч Энд Девелопмент Гмбх filed Critical Фибрекс Медикал Рисерч Энд Девелопмент Гмбх (At)
Publication of RU2008130413A publication Critical patent/RU2008130413A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
RU2008130413/15A 2005-12-23 2006-11-10 Фармацевтическая композиция для лечения геморрагического шока и его последствий RU2008130413A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0206705A AT502987A1 (de) 2005-12-23 2005-12-23 Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen
ATA2067/2005 2005-12-23

Publications (1)

Publication Number Publication Date
RU2008130413A true RU2008130413A (ru) 2010-01-27

Family

ID=37846035

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008130413/15A RU2008130413A (ru) 2005-12-23 2006-11-10 Фармацевтическая композиция для лечения геморрагического шока и его последствий

Country Status (14)

Country Link
US (1) US7897574B2 (cg-RX-API-DMAC7.html)
EP (2) EP2110136A3 (cg-RX-API-DMAC7.html)
JP (1) JP2009520696A (cg-RX-API-DMAC7.html)
KR (1) KR20080108221A (cg-RX-API-DMAC7.html)
CN (1) CN101365477A (cg-RX-API-DMAC7.html)
AT (2) AT502987A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006326890A1 (cg-RX-API-DMAC7.html)
CA (1) CA2634026A1 (cg-RX-API-DMAC7.html)
DE (1) DE502006004619D1 (cg-RX-API-DMAC7.html)
ES (1) ES2331970T3 (cg-RX-API-DMAC7.html)
IL (1) IL192349A0 (cg-RX-API-DMAC7.html)
NO (1) NO20083191L (cg-RX-API-DMAC7.html)
RU (1) RU2008130413A (cg-RX-API-DMAC7.html)
WO (1) WO2007070899A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799758B2 (en) * 2006-02-23 2010-09-21 Ikaria Development Subsidiary Two, LLC Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
EP2193370A2 (en) * 2007-09-24 2010-06-09 Fibrex Medical Research & Development GmbH Methods of screening for compounds having anti-inflammatory activity
WO2012078736A2 (en) * 2010-12-09 2012-06-14 The Brigham And Women's Hospital, Inc. Fibrinogen and kidney damage
US20170112941A1 (en) * 2015-10-13 2017-04-27 Symic Ip, Llc Ve-cadherin binding bioconjugate
JP7506364B2 (ja) * 2019-10-24 2024-06-26 国立大学法人東海国立大学機構 慢性肺疾患/急性呼吸窮迫症候群の治療薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997844A (en) 1991-02-08 1999-12-07 Diatide, Inc. Technetium-99m labeled peptides for imaging
CN1518558B (zh) 2000-12-12 2010-06-16 菲布雷克斯医疗研究及开发有限责任公司 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途
US20080311103A1 (en) * 2004-03-08 2008-12-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Anti-Inflammatory Peptides and Methods of Use Thereof
AT414097B (de) 2004-06-25 2006-09-15 Petzelbauer Peter Dr Pharmazeutische zubereitung zur behandlung von schock
PT1691827E (pt) 2004-06-25 2009-11-23 Fibrex Medical Res & Dev Gmbh Utilização de péptidos derivados da cadeia b beta de fibrinogénio humano para o tratamento do choque

Also Published As

Publication number Publication date
US7897574B2 (en) 2011-03-01
ES2331970T3 (es) 2010-01-21
EP1962887A2 (de) 2008-09-03
IL192349A0 (en) 2008-12-29
WO2007070899A2 (de) 2007-06-28
WO2007070899A3 (de) 2007-10-04
AT502987A1 (de) 2007-07-15
CA2634026A1 (en) 2007-06-28
NO20083191L (no) 2008-09-16
AU2006326890A1 (en) 2007-06-28
KR20080108221A (ko) 2008-12-12
EP2110136A3 (de) 2010-01-27
US20090005310A1 (en) 2009-01-01
EP2110136A2 (de) 2009-10-21
CN101365477A (zh) 2009-02-11
EP1962887B1 (de) 2009-08-19
ATE440282T1 (de) 2009-09-15
DE502006004619D1 (de) 2009-10-01
JP2009520696A (ja) 2009-05-28

Similar Documents

Publication Publication Date Title
Jia et al. Mechanical stretch‐induced endoplasmic reticulum stress, apoptosis and inflammation contribute to thoracic aortic aneurysm and dissection
Wang et al. Involvement of macrophage-derived exosomes in abdominal aortic aneurysms development
Borensztajn et al. Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activation
Lovric-Bencic et al. Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse
Jalan et al. Pathogenesis of intracranial hypertension in acute liver failure: inflammation, ammonia and cerebral blood flow
Bige et al. Thrombospondin-1 plays a profibrotic and pro-inflammatory role during ureteric obstruction
Dashwood et al. Effect of vein graft harvesting on endothelial nitric oxide synthase and nitric oxide production
Faries et al. The role of surgical revascularization in the management of diabetic foot wounds
Yoshiya et al. Blockade of the apelin–APJ system promotes mouse liver regeneration by activating Kupffer cells after partial hepatectomy
Nergui et al. Role of endothelial nitric oxide synthase and collagen metabolism in right ventricular remodeling due to pulmonary hypertension
Ren et al. AEBP1 promotes the occurrence and development of abdominal aortic aneurysm by modulating inflammation via the NF-κB pathway
Farberov et al. Functions and transcriptional regulation of thrombospondins and their interrelationship with fibroblast growth factor-2 in bovine luteal cells
Liu et al. Ticagrelor attenuates myocardial ischaemia–reperfusion injury possibly through downregulating galectin‐3 expression in the infarct area of rats
Zhang et al. Up-regulation of components of the renin–angiotensin system in liver fibrosis in the rat induced by CCL4
NO20083191L (no) Farmasoytisk sammensetning for behandling av hemoragisk sjokk og dens etterfolgende symptomer
Vila Cuenca et al. Differences in peritoneal response after exposure to low-GDP bicarbonate/lactate-buffered dialysis solution compared to conventional dialysis solution in a uremic mouse model
Chi et al. Knockdown of myeloid differentiation protein-2 reduces acute lung injury following orthotopic autologous liver transplantation in a rat model
Warzecha et al. Influence of ischemic preconditioning on blood coagulation, fibrinolytic activity and pancreatic repair in the course of caerulein-induced acute pancreatitis in rats
Shang et al. Tanshinone IIA attenuates elastase-induced AAA in rats via inhibition of MyD88-dependent TLR-4 signaling
Dai et al. Ruscogenin alleviates deep venous thrombosis and pulmonary embolism induced by inferior vena cava stenosis inhibiting MEK/ERK/Egr-1/TF signaling pathway in mice
Hu et al. Fasudil prevents calcium oxalate crystal deposit and renal fibrogenesis in glyoxylate-induced nephrolithic mice
Zheng et al. Mineralocorticoid receptor negatively regulates angiogenesis through repression of STAT3 activity in endothelial cells
Nowińska et al. Changes in the pancreas caused by different types of hypertension
JP2009520696A5 (cg-RX-API-DMAC7.html)
Wang et al. Serum neutrophil gelatinase-associated lipocalin and proinflammatory cytokines in pigs with septic versus non-septic acute kidney injury

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20110815